Femara and Osteomyelitis chronic - a phase IV clinical study of FDA data

Summary:

Osteomyelitis chronic is reported as a side effect among people who take Femara (letrozole), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Zometa, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Osteomyelitis chronic when taking Femara. It is created by eHealthMe based on reports of 19,093 people who have side effects when taking Femara from the FDA, and is updated regularly.

What is Femara?

Femara has active ingredients of letrozole. It is often used in breast cancer. eHealthMe is studying from 19,630 Femara users. Check the latest studies of Femara.

What is Osteomyelitis chronic?

Osteomyelitis chronic (long lasting infection of bone marrow) is found to be associated with 240 drugs and 223 conditions by eHealthMe. Check the latest studies of Osteomyelitis chronic.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

19,093 people reported to have side effects when taking Femara.
Among them, 59 people (0.31%) have Osteomyelitis chronic.

Could Femara cause Osteomyelitis chronic?

Among these 59 people:

How long have people been on Femara when they have Osteomyelitis chronic? *

What is the gender of people who have Osteomyelitis chronic when taking Femara? *

female: 94.92 %
male: 5.08 %

What is the age of people who have Osteomyelitis chronic when taking Femara? *

What are other drugs people take besides Femara? *

What are other side effects people have besides Osteomyelitis chronic? *

Bone Disorder: 47 people, 79.66%
Pain In Jaw: 43 people, 72.88%
Tooth Disorder (tooth disease): 37 people, 62.71%
Osteonecrosis Of Jaw (death of bone of jaw): 33 people, 55.93%
Pain: 32 people, 54.24%
Injury: 30 people, 50.85%
Pleural Effusion (water on the lungs): 30 people, 50.85%
Fistula (an abnormal connection or passageway between two): 29 people, 49.15%
Chest Pain: 29 people, 49.15%
Primary Sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone): 29 people, 49.15%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 20 people, 33.90%
Metastases To Bone (cancer spreads to bone): 15 people, 25.42%
Osteoporosis (bones weak and more likely to break): 2 people, 3.39%
Pain: 1 person, 1.69%
Otitis (ear infection): 1 person, 1.69%
Hypersensitivity: 1 person, 1.69%
High Blood Pressure: 1 person, 1.69%
Bone Loss: 1 person, 1.69%

* Approximation only. Some reports may have incomplete information.

Do you take Femara and have Osteomyelitis chronic?

- Check whether Osteomyelitis chronic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Femara:

Femara (19,630 reports)

Browse all side effects of Femara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteomyelitis chronic:

Osteomyelitis chronic (240 drugs)

Browse all the conditions that are associated with Osteomyelitis chronic:

Osteomyelitis chronic (223 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on letrozole (the active ingredients of Femara) and Femara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.